This poster outlines a novel engineered platform for the formulation of high-active-loading oral solid dosage forms containing amorphous solid dispersions (ASDs) of a rapidly crystallizing drug with a low glass-transition temperature (Tg). An engineered dosage form architecture is used that divides the work of performance and stability across the ASD intermediate and final dosage from, demonstrating excellent performance, stability, and manufacturability, while reducing the pill burden 40% below that of the benchmark tablet formulation. To learn more, please review our poster.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center